Our Services

Cancer Drug Candidate Development

Cancer Drug Candidate Development

Led by a group of expert scientists, BRI involves in the following areas of cancer drug discovery and development activities:

– Cancer molecular target genetic screening
– Cancer cell biology and pharmacology
– Patient-derived orthotopic subrenal capsule xenograft mouse model development
– Unique In vivo DM/PK/ADME characterization of “drug-like” properties in patient-derived xenograft
– Integrated LC/MS/MS and biological assays supporting discovery and IND and NDA-enabling development studies

ANTI-CANCER DRUG DISCOVERY & DEVELOPMENT

In Vitro Cell Line Anticancer Activity Screening

– Drug efficacy screening assays using commercial ATCC human cancer cell lines with known genetic characteristization

In Vivo Cell Line Xenograft Drug Efficacy Study

– Utilize commercial cell lines or cell line provided by sponsor to generate subcutaneous, subrenal capsule or other orthotopic xenograft models for drug efficacy studies
– Generate pharmacokinetic data from the same experiment based on serial blood sampling for LC/MS/MS assay to provide PK/PD correlation

In Vivo Patient-Derived Orthotopic Xenograft Translational Efficacy Study

– Translational efficacy study based on patient-derived tumors established in NOD-SCID mice
– Highly recognized expertise and excellent track record on development of patient-derived tumor xenografts of various cancers including cancers the prostate, ovary, lung, pancreas, skin, uterus, colon, kidney, bone, breast sarcoma and lymphoma
– Generate pharmacokinetic data from the same experiment based on serial blood sampling for LC/MS/MS assay to provide PK/PD correlation

Uniquely Integrated “all-in-one” In Vivo Anticancer Drug Efficacy Study Design

– Inhibition of tumor growth and metastases efficacy endpoints
– Pharmacokinetics and ADME data for PK/PD correlation
– Survival endpoint and adverse events monitoring
– Histopathological evaluation
– Molecular targets and biomarker evaluation